Clinical Genitourinary Cancer

Journal Information
ISSN / EISSN : 1558-7673 / 1938-0682
Current Publisher: Elsevier (10.1016)
Former Publisher: Elsevier BV (10.3816)
Total articles ≅ 1,898
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Giuseppe Di Lorenzo, Silvia Zappavigna, Felice Crocetto, Mario Giuliano, Dario Ribera, Rocco Morra, Luca Scafuri, Antonio Verde, Dario Bruzzese, Simona Iaccarino, et al.
Published: 1 April 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2021.03.021

The publisher has not yet granted permission to display this abstract.
Rémi Pelloux-Prayer, Philomène Schiele, Stéphane Oudard, Gwenaëlle Gravis, François Kleinclauss, Gilles Crehange, Christophe Hennequin, Alicia K. Morgans, Lionel Geoffrois, Samuel Limat, et al.
Published: 1 April 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2021.03.022

The publisher has not yet granted permission to display this abstract.
A. Hijab, S. Curcean, , H. Tovey, R. Alonzi, J. Staffurth, M.D. Blackledge, , A. Tree, H. Stidwill, et al.
Published: 1 April 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2021.03.020

Abstract:
Background Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is unclear. Patients and Methods Prospective, multicentre phase II study of radium-223 in 36 men with mCRPC, and a reference cohort (n=36), matched for fracture risk, not treated with radium-223. Bone fractures were assessed using whole body MRI (WB MR). The primary outcome was risk of new fractures. Results 36 patients were treated with up to six 4-weekly cycles of radium-223. With a median follow-up 16.3 months, 74 new fractures were identified in 20 patients. Freedom from fracture was 56% (95% CI: 35.3-71.6) at 12 months. On multivariate analysis, prior corticosteroid use was associated with risk of fracture. In the reference cohort (n=36), 16 new fractures were identified in 12 patients over median 24 months follow-up. 67% of all fractures across both cohorts occurred at uninvolved bone. Conclusions Men with mCRPC, and particularly those treated with radium-223, are at risk of fracture. They should receive a bone health agent to reduce risk of fragility fractures.
, Marieke J. Krimphove, L. Franziska Stolzenbach, , , Mila Mansour, Zhe Tian, Frederik C. Roos, Andreas Becker, Luis A. Kluth, et al.
Published: 1 April 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2021.03.010

The publisher has not yet granted permission to display this abstract.
, Michael N. Needle, , Sumanta K. Pal, , Michael B. Atkins, Thomas E. Hutson, Bernard J. Escudier
Published: 1 April 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2021.03.018

Abstract:
Background In TIVO-3, tivozanib increased progression-free survival with no difference in overall survival relative to sorafenib as 3rd- or 4th-line therapy in patients with metastatic RCC. We applied quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) methods to quantify the net health benefits of tivozanib, in the presence of similar survival, when compared to sorafenib. Methods Mean Q-TWiST was calculated by applying utility coefficients of 0.5, 1.0, and 0.5 to the 36-month restricted mean health states of time with toxicity (TOX), time without symptoms and toxicity (TWiST), and time after progression/relapse (REL), respectively. Relative Q-TWiST gain was defined as the mean absolute Q-TWiST difference divided by the sorafenib mean OS. Results Mean TWiST was longer for tivozanib than for sorafenib, mean REL was shorter for tivozanib, with no difference in mean TOX. Mean Q-TWiST was 15.04 months and 12.78 months for tivozanib and sorafenib, respectively (p = 0.0493). The tivozanib relative gain was 11.2%. Discussion Tivozanib increased Q-TWiST relative to sorafenib, primarily through an increase in TWiST, which is generally considered to be the highest utility state. Conclusion Q-TWiST may be considered an alternative patient-centered measure of benefit of tivozanib in as a 3rd- or 4th-line therapy in patients with RCC. Clinical trial information NCT02627963 Micro abstract In TIVO-3, tivozanib increased progression-free survival relative to sorafenib in patients with metastatic renal cell carcinoma (RCC). In the current analysis, tivozanib also increased quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) . As an outcome that integrates the quantity and quality of survival, Q-TWiST may be considered an alternative patient-centered measure of tivozanib benefit in RCC.
Grant M. Henning, Nimrod S. Barashi,
Published: 1 March 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2020.12.003

The publisher has not yet granted permission to display this abstract.
, Joseph Renzulli, Kara Olivier, Neal D. Shore
Published: 1 March 2021
Clinical Genitourinary Cancer; doi:10.1016/j.clgc.2021.03.014

The publisher has not yet granted permission to display this abstract.
Back to Top Top